GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Hikal Ltd

Hikal Q2 FY27 Consolidated Revenue Rs. 434 Cr, Net Loss Rs. 6 Cr

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 04:09 PM IST  ·  BSE ID: be5fc071-017f-436a-b554-b18f5468bd27
View Original BSE Filing (PDF)
💡
In Simple Terms
Hikal's total revenue grew to Rs. 434 crore in Q2 FY27, with reduced losses of Rs. 6 crore compared to last year.
🤖 AI Summary
  • Hikal Ltd reported Q2 FY27 consolidated revenue of Rs. 434 crores, a 36% increase from Q2 FY26.
  • Consolidated Net Profit was a loss of Rs. 6 crores for Q2 FY27, improving 83% from Rs. (35) crores in Q2 FY26.
  • Pharmaceuticals segment revenue grew 47% YoY to Rs. 278 crores, showing improved EBIT margins.
  • Crop Protection segment revenue reached Rs. 156 crores, up 21% YoY, despite operating challenges.
  • Consolidated EBITDA for Q2 FY27 stood at Rs. 45 crores, resulting in an EBITDA margin of 10.3%.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue Q2 FY27
Rs. 434 crores
36%
Consolidated Net Profit Q2 FY27
Rs. (6) crores
83%
Pharmaceuticals Revenue Q2 FY27
Rs. 278 crores
47%
Crop Protection Revenue Q2 FY27
Rs. 156 crores
21%
Consolidated EBITDA Q2 FY27
Rs. 45 crores
524%
Consolidated H1 FY27 Revenue
Rs. 837 crores
20%
Consolidated H1 FY27 Net Profit
Rs. (14) crores
76%
🏢 How This Affects the Company
📈
Business Impact
The Pharmaceuticals business continued its recovery with growth in the established API portfolio and expanded CDMO pipeline. The Personal Care business commenced commercial production at its new Panoli facility.
💰
Financial Impact
Consolidated revenue increased by 36% YoY to Rs. 434 crores, and the net loss significantly narrowed by 83% YoY to Rs. 6 crores. EBITDA improved to Rs. 45 crores with a margin of 10.3%.
⚙️
Operational Impact
The Bengaluru API facility received GMP certification from Swissmedic, enhancing regulatory compliance. Commercial production started for Personal Care at Panoli, adding new manufacturing capabilities.
⚠️
Risk Impact
The Crop Protection business continued to navigate challenges from elevated raw material and energy prices, deferred demand, and pricing pressure, which impacted margins.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this results presentation.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with the Q2 FY27 consolidated net loss of Rs. (6) crores impacting earnings per share at Rs. (0.49).
🔍
Management Signal
Management indicates confidence in H2 FY27 growth and reiterates full-year guidance of mid-teens revenue growth and substantial profitability improvement.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 financial results — check if revenue and profitability sustain recovery.
Updates on CDMO pipeline conversion and new product commercialisation.
Progress on Crop Protection segment's margin improvement and demand stability.
MEDIUM RISK Ongoing challenges in Crop Protection and continued consolidated losses, despite significant improvement.
💡 Investor Takeaway
Hikal Ltd reported consolidated revenue of Rs. 434 crores in Q2 FY27, marking a 36% YoY increase. The net loss significantly narrowed by 83% YoY to Rs. (6) crores. Pharmaceuticals revenue grew 47% YoY to Rs. 278 crores, while Crop Protection revenue increased 21% YoY to Rs. 156 crores.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated revenue increased 36% YoY to Rs. 434 crores in Q2 FY27, reflecting a business recovery.
  • Consolidated Net Loss improved by 83% YoY to Rs. (6) crores in Q2 FY27, reducing prior period losses significantly.

⚠️ Concerns

  • Crop Protection business EBIT remained negative at Rs. (2) crores in Q2 FY27, impacted by raw material and energy costs.
  • Consolidated PBT before exceptional items for Q2 FY27 was a loss of Rs. (8) crores, indicating ongoing pre-tax losses.
📅 Company Track Record
In Q1 FY27, Hikal reported a standalone net loss of Rs. 75 Million on Rs. 4,028 Million revenue. Q4 FY26 standalone net profit was Rs. 146 Million, with a recommended final dividend of ₹ 0.40/share. Q2 FY27 results show a reduced loss compared to Q2 FY26's consolidated loss of Rs. 35 crores.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Hikal Ltd's consolidated revenue for Q2 FY27?
Hikal Ltd reported a consolidated revenue of Rs. 434 crores for the quarter ended September 30, 2026 (Q2 FY27).
What was Hikal Ltd's consolidated net profit/loss in Q2 FY27?
Hikal Ltd reported a consolidated net loss of Rs. (6) crores for Q2 FY27, which is an 83% improvement from a loss of Rs. (35) crores in Q2 FY26.
How did Hikal's Pharmaceuticals segment perform in Q2 FY27?
The Pharmaceuticals segment revenue for Hikal Ltd grew by 47% YoY to Rs. 278 crores in Q2 FY27, with an EBIT of Rs. 13 crores.
What was the performance of Hikal's Crop Protection business in Q2 FY27?
Hikal's Crop Protection business revenue for Q2 FY27 was Rs. 156 crores, showing a 21% YoY growth, despite reporting an EBIT of Rs. (2) crores.
What was Hikal Ltd's consolidated EBITDA for Q2 FY27?
Hikal Ltd's consolidated EBITDA for Q2 FY27 was Rs. 45 crores, resulting in an EBITDA margin of 10.3%.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.